| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD40 |
| Uniprot No | P25942 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-193aa |
| 氨基酸序列 | EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDT WNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV LHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETK DLVVQQAGTNKTDVVCGPQDRLR |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD40重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*CD40 Agonist Antibodies in Cancer Immunotherapy*
**作者**：Vonderheide, R.H.
**摘要**：探讨了重组CD40激动剂抗体在激活抗原呈递细胞(如树突状细胞)中的作用，通过增强T细胞抗肿瘤免疫反应，展示了其在临床试验中治疗多种实体瘤的潜力。
2. **文献名称**：*Targeting CD40 Combined with PD-1 Blockade Enhances Antitumor Immune Responses*
**作者**：Melero, I., et al.
**摘要**：研究了重组CD40配体蛋白与PD-1抑制剂联合使用的协同效应，证明该策略可显著提升肿瘤微环境中T细胞的浸润和杀伤功能，为联合免疫治疗提供新方向。
3. **文献名称**：*Recombinant CD40L Protein as a Vaccine Adjuvant for Inducing Humoral Immunity*
**作者**：Piechutta, M., et al.
**摘要**：评估了重组CD40L蛋白作为疫苗佐剂的效果，发现其通过激活B细胞和增强抗体产生，显著提高疫苗诱导的抗原特异性免疫应答，适用于感染性疾病预防。
4. **文献名称**：*CD40/CD40L Signaling in Autoimmunity and Its Inhibition as a Therapeutic Strategy*
**作者**：Karnell, J.L., et al.
**摘要**：分析了重组可溶性CD40蛋白阻断CD40-CD40L相互作用的机制，验证其在抑制自身免疫性疾病(如类风湿关节炎)中过度免疫激活的效果，为靶向治疗提供依据。
以上文献涵盖CD40重组蛋白在肿瘤免疫、疫苗开发及自身免疫疾病中的关键机制与应用方向。
CD40 recombinant protein is a biologically engineered molecule derived from the CD40 receptor, a critical component of the immune system. CD40. a member of the tumor necrosis factor (TNF) receptor superfamily, is primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. Its interaction with CD40 ligand (CD40L/CD154) on activated T cells plays a pivotal role in adaptive immunity, regulating processes like antibody class switching, germinal center formation, and T-cell priming. Dysregulation of CD40 signaling is implicated in autoimmune diseases, cancer, and chronic inflammation.
Recombinant CD40 proteins are typically produced in mammalian expression systems (e.g., CHO or HEK293 cells) or bacterial systems (e.g., E. coli) to ensure proper folding and post-translational modifications. These proteins may exist as soluble forms (e.g., extracellular domains) or fusion constructs (e.g., Fc-tagged variants) to enhance stability and functionality. In research and therapeutic contexts, CD40 recombinant proteins are used to modulate immune responses. Agonistic CD40 antibodies or CD40L mimics can activate APCs, potentially boosting anti-tumor immunity or vaccine efficacy. Conversely, antagonistic CD40 proteins may suppress excessive immune activation in autoimmune conditions.
Therapeutic applications focus heavily on cancer immunotherapy, where CD40 activation promotes dendritic cell maturation and cross-presentation of tumor antigens. Clinical trials have explored CD40 agonists in combination with checkpoint inhibitors or chemotherapy. Challenges include balancing efficacy with systemic toxicity, as uncontrolled CD40 activation may trigger cytokine storms. Recent advances in structural biology have enabled the design of hexameric CD40 agonists with improved specificity and reduced off-target effects. Additionally, species-specific variations in CD40-CD40L interactions necessitate careful preclinical evaluation when translating findings from animal models to humans. Ongoing research aims to optimize delivery systems (e.g., nanoparticles) and combination therapies to maximize clinical benefit while minimizing adverse effects.
×
